Drugs / ACE1831
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05653271 | Jan 2023 → Mar 2026 | Burkitt lymphoma, follicular lymphoma, high grade B-cell lymphoma, marginal zone lymphoma +1 | Acepodia Biotech, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07061938 | Jan 2026 → Jan 2027 expected | immunoglobulin G4-related sclerosing disease | Acepodia Biotech, Inc. | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07314567 | Jan 2026 → Oct 2027 expected | systemic lupus erythematosus | Tongji Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACE1831 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07061938 ↗ |
| Modality | Cell therapy | “Allogeneic gamma delta T (gdT) cell therapy” NCT05653271 ↗ |